Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
about
Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review.The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies.Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled AnalysisComparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions.XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?A practical guide to the handling and administration of talimogene laherparepvec in Europe.Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma.Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
P2860
Q26749119-09B0FFB3-0C80-4437-94DE-BFAAA6A96BBFQ30882874-FDDE3CA6-5F51-4A83-AB3D-7B1565F5772BQ33733507-F8A13DEF-4494-43D1-8558-CDBA8B08AC38Q35148109-B3592795-378E-4BEA-A73F-B13AA9E5D3CDQ35739540-92836EFA-7DD8-49CF-B8A2-716514CEB089Q36897213-41333A5A-F620-4BE6-A572-8350BACB7083Q37046433-AF18765B-CDED-41D8-8248-C22E3C0D5DB5Q37636844-D52C64A5-8927-42D6-8CB4-85F2961D48D6Q37863631-31E147F5-5625-493A-8773-1D2EF671C204Q38072637-6671F8B0-3A25-4E9F-9894-92565C2460D7Q38343383-7094AF35-9EAC-480B-9EF9-78F7DDC9AB61Q40080717-5D906281-B597-450C-93DD-E20913198943Q41470825-4EB1F121-FAE8-4D57-8447-A0399B59F97DQ45718951-A595976C-1F34-4E50-8423-42A155FC2427
P2860
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@en
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@nl
type
label
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@en
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@nl
prefLabel
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@en
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@nl
P2093
P2860
P1476
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
@en
P2093
Gang-Hong Lee
Hyan-Chul Rhim
In-Soon Kim
Jin-Woo Kim
Jung-Hye Choi
Myung-Ju Ahn
Young-Yeul Lee
P2860
P304
P356
10.4143/CRT.2005.37.5.290
P577
2005-10-31T00:00:00Z